US Executive Compensation Proxy SEC Filings — September 11, 2026

11-09-2026

Annovis Bio, Inc. is holding a Special Meeting to seek stockholder approval for two proposals: (1) increasing authorized Common Stock from 70,000,000 to 140,000,000 shares and Preferred Stock from 2,000,000 to 10,000,000 shares, and (2) ratifying an amendment to the 2019 Equity Incentive Plan to increase the share reserve by 2,500,000 shares (to 5,500,000 total) and raise the annual award limit from 400,000 to 600,000 shares. The company highlights significant working capital needs and the necessity of additional equity financing to fund ongoing and future clinical trials. The board unanimously recommends voting 'FOR' both proposals, while acknowledging potential dilution to existing stockholders as a key disadvantage.

• · As of the Record Date, 42,679,059 shares of Common Stock were outstanding out of 70,000,000 authorized, and no shares of Preferred Stock were issued or outstanding.
• · An aggregate of approximately 21,210,026 shares of Common Stock are issuable as of the Record Date, including 2,826,054 from outstanding stock options, 173,946 reserved under the 2019 Equity Incentive Plan, and 18,210,026 from outstanding warrants.
• · Only 6,110,915 shares of Common Stock remained available for future issuance as of September 4, 2026.
• · The Share Increase Amendment is not related to any plans for a merger, consolidation, acquisition, or similar business combination.
• · The company has not issued any shares of Preferred Stock to date.
• · The ratification proposal stems from a typographical error in the June 2026 Annual Meeting disclosure regarding the incremental share increase (stated 1,000,000 instead of 2,500,000).
• · No new grants have been made under the Plan since the June 2026 Annual Meeting.
• · The Plan's history: 1,000,000 shares initially authorized, increased to 2,000,000 in 2021, and by an additional 1,000,000 in 2024.
• · In December 2025, the Board approved option grants contingent upon stockholder approval of the Plan increase to 5,500,000 shares and the annual award limit increase to 600,000 shares.
• · As of December 31, 2025, 2,394,503 equity-based awards were outstanding under the Plan (excluding exercised and December contingent grants).
• · If stockholders do not ratify the share increase, the company believes it will not be able to offer competitive equity packages, which could hamper growth and operations.
• · The company's working capital requirements are significant and may require additional equity financings in the future.
• · The board unanimously recommends voting 'FOR' both proposals.
• · Abstentions and broker non-votes will have the same effect as votes against Proposal 1.

11-09-2026

Russell Investment Funds filed a definitive proxy statement (DEF 14A) for a special shareholder meeting on November 24, 2026, to vote on three proposals: (1) approval of a new investment advisory agreement with Russell Investment Management, LLC (RIM) following the $2.8 billion acquisition of Russell Investments by a consortium led by B Capital and including CalPERS; (2) a Manager of Managers proposal for certain funds to permit RIM to enter into and materially amend subadvisory agreements with affiliated money managers without shareholder approval; and (3) election of Trustee Ellen M. Needham. The Board unanimously recommends voting in favor of all proposals. The transaction does not change advisory fees, investment strategies, or total expense ratios for the funds.

• · The special meeting will be held on November 24, 2026 at 11:00 a.m. Pacific Time at Russell Investments offices in Seattle, WA.
• · Record date for shareholders entitled to vote is September 1, 2026.
• · The transaction is expected to close with CalPERS owning indirectly a majority non-voting interest of BEAM Topco.
• · The Funds will not bear any portion of the costs associated with the Transaction.
• · The Manager of Managers Proposal applies only to shareholders of funds other than the four LifePoints Funds (Moderate Strategy, Balanced Strategy, Aggressive Strategy, Equity Aggressive Strategy).
• · The Trustee Nominee, Ellen M. Needham, has not previously been elected by shareholders.

11-09-2026

Sachem Capital Corp. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting, seeking shareholder votes on director elections, an advisory say-on-pay resolution, and ratification of auditor Baker Tilly. The filing discloses executive compensation details and equity grant activity under the 2025 Omnibus Incentive Plan. No financial results or period-over-period comparisons are provided in this filing.

• · Audit Committee pre-approved 100% of services provided by Baker Tilly during fiscal 2025.
• · No stock options, stock appreciation rights, or restricted stock units were granted under the 2025 Plan as of December 31, 2025.
• · Shareholder proposals for the 2027 Annual Meeting must be submitted by May 14, 2027.
• · Director nominations for the 2027 Annual Meeting must be submitted between June 24, 2027 and July 24, 2027.

11-09-2026

Wolfspeed, Inc. filed its definitive proxy statement (DEF 14A) on September 11, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on October 27, 2026. The agenda includes the election of seven directors, approval of a new 2026 Employee Stock Purchase Plan, an advisory vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors. The filing highlights a nearly entirely refreshed board, with all seven director nominees having joined between May and September 2025 (plus one in July 2026), and a new CEO, Robert A. Feurle, appointed in May 2025.

• · Annual Meeting will be held virtually at www.virtualshareholdermeeting.com/WOLF2026 on October 27, 2026 at 12:00 p.m. Eastern time.
• · Record date for voting is August 31, 2026.
• · Proxy materials will be made available on the Internet on or about September 15, 2026.
• · Proposal No. 2 is the approval of the 2026 Employee Stock Purchase Plan (ESPP), which requires stockholder approval.
• · Proposal No. 3 is an advisory (nonbinding) vote on executive compensation.
• · Proposal No. 4 is the ratification of PwC as independent auditors for fiscal year ending June 27, 2027.
• · The board recommends a FOR vote on all proposals.
• · Executive officers include Robert A. Feurle (CEO), Gregor van Issum (CFO), David T. Emerson (COO), and Bradley D. Kohn (Chief Legal and Global Affairs Officer).

11-09-2026

Carpenter Technology Corp filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders, scheduled for October 6, 2026. The board recommends voting for all three director nominees (Steven E. Karol, Charles D. McLane, Jr., Tony R. Thene), ratification of PricewaterhouseCoopers as auditors, and an advisory vote on executive compensation. The filing highlights governance practices including 11 of 12 independent directors, majority voting, and double-trigger change-in-control benefits, but provides no financial performance data or period-over-period comparisons.

• · Annual Meeting: October 6, 2026, 11:00 a.m., virtual at www.virtualshareholdermeeting.com/CRS2026
• · Record date: August 7, 2026
• · Proxy statement sent to stockholders on or about September 11, 2026
• · Board committees: Strategy (Chair: Steven E. Karol), Audit/Finance (Chair: Charles D. McLane, Jr.), Corporate Governance, Human Capital Management
• · Board refreshment: 0 new directors added in FY 2026; 2 added in FY 2025 (Julie A. Beck, Howard H. Yu); 0 in FY 2024
• · Director resignation policy for uncontested elections in place
• · Independent compensation consultants engaged for Human Capital Management Committee

11-09-2026

Supernus Pharmaceuticals, Inc. (SUPN) is being acquired by Indivior Pharmaceuticals, Inc. (INDV) in an all-stock merger. Each Supernus share will be converted into the right to receive 1.5401 Indivior shares, with no cash consideration. The merger is subject to stockholder approvals from both companies and other customary conditions, and no appraisal rights are available to holders of either company's shares.

• · The record date for both the Indivior and Supernus special meetings is the close of business on September 4, 2026.
• · Indivior was incorporated in Delaware on October 28, 2025, and became the ultimate parent company of Indivior PLC on January 23, 2026, after a change of corporate domicile to the United States.
• · Supernus equity awards will be assumed by Indivior and converted into corresponding awards covering Indivior shares, with the number of underlying shares and exercise price adjusted by the exchange ratio of 1.5401.
• · Indivior's common stock trades on the Nasdaq Global Select Market under the ticker symbol 'INDV'.
• · Supernus' common stock trades on the Nasdaq Global Market under the symbol 'SUPN'.

11-09-2026

Jaguar Uranium Corp. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders to be held on September 22, 2026. Shareholders will vote on the election of six directors, an amendment to the 2025 Equity Incentive Plan, and ratification of Davidson & Company LLP as independent auditors. The board unanimously recommends voting 'For' all proposals. The company has 20,193,777 Class A common shares issued and outstanding.

• · Meeting format: virtual-only via Zoom
• · Record date is August 10, 2026
• · Six directors to be elected
• · Proposal to amend the 2025 Equity Incentive Plan
• · Quorum requires two persons holding at least 1/20 of issued shares

11-09-2026

Russell Investments Exchange Traded Funds is soliciting shareholder approval for a new investment advisory agreement following the $2.8B all-cash acquisition of Russell Investments Group by an investor consortium led by B Capital and including CalPERS. The transaction will result in a change of control of RIM, triggering the need for a new advisory agreement with identical terms and fee rates. Shareholders are also asked to permit RIM to enter into and materially amend subadvisory agreements with affiliated managers without further approval, and to approve a revision to the concentration restriction for the Global Infrastructure ETF. The Board unanimously recommends voting in favor of all proposals.

• · The special shareholder meeting will be held on November 24, 2026 at 11:00 a.m. Pacific Time at 401 Union Street, 18th Floor, Seattle, WA 98101.
• · Record date for determining shareholders entitled to vote is September 1, 2026.
• · The Post-Transaction Agreement does not change the advisory fee rate or total expense ratio for any Fund.
• · The Funds will not bear any portion of the costs associated with the Transaction.
• · CalPERS is anticipated to own indirectly a majority non-voting interest of BEAM Topco at closing.
• · RIM and its affiliated investment advisers will guarantee the debt incurred in connection with the closing.
• · The Transaction is expected to be funded from debt and equity financing sources, including a senior secured term loan and revolving credit facility.

11-09-2026

Russell Investment Company is soliciting shareholder approval for a new investment advisory agreement following the $2.8 billion all-cash acquisition of Russell Investments Group by a consortium led by B Capital and including CalPERS. The transaction will result in a change of control of RIM, requiring a new advisory agreement with identical fee terms. Shareholders are also asked to vote on permitting RIM to enter into subadvisory agreements with affiliated managers without shareholder approval, a revision to the concentration restriction for the Global Infrastructure Fund, and the election of one trustee.

• · The special shareholder meeting is scheduled for November 24, 2026, at 11:00 a.m. Pacific Time in Seattle, WA.
• · Record date for voting is September 1, 2026.
• · The new advisory agreement does not change the investment advisory fee rate for any Fund.
• · CalPERS is anticipated to own indirectly a majority non-voting interest of BEAM Topco at closing.
• · The transaction is valued at $2.8 billion in cash, funded from debt and equity financing sources.
• · RIM and its affiliated investment advisers will guarantee the debt incurred by Russell Investments US Institutional Holdco, Inc. and Russell Investments US Retail Holdco, Inc. in connection with closing.

11-09-2026

Unifi, Inc. (UFI) filed its definitive proxy statement (DEF 14A) on September 11, 2026, for the Annual Meeting of Shareholders to be held on October 27, 2026. Key proposals include the election of eight directors, an advisory vote on named executive officer compensation for fiscal 2026, and ratification of KPMG LLP as independent auditor for fiscal 2027. The filing details executive compensation, corporate governance, and security ownership.

11-09-2026

aTyr Pharma, Inc. filed a definitive proxy statement (DEF 14A) for a Special Meeting of Stockholders to be held on October 16, 2026. The sole proposal is to approve a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-50, as determined by the Board. The Board unanimously recommends a vote 'FOR' the proposal.

• · Special Meeting date: October 16, 2026 at 9:00 a.m. Pacific Time at the Company's headquarters in San Diego, CA.
• · Record date for voting: September 4, 2026.
• · Proxy materials mailed on or about September 11, 2026.
• · Reverse stock split ratio range: 1-for-10 to 1-for-50, inclusive.
• · The reverse stock split proposal is considered a 'routine' matter under NYSE rules, allowing brokers to vote uninstructed shares.
• · Stockholders of record may vote via internet, telephone, or mail by October 15, 2026 at 11:59 p.m. Eastern Time.